Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 64Neoplasms 8Sarcoma 6Ovarian Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Sarcoma, Ewing 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Rhabdomyosarcoma 3Rhabdoid Tumor 3Prostatic Neoplasms 3Osteosarcoma 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Lymphoma 3Liposarcoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Kidney Neoplasms 2

Interventions

palbociclib 2Fulvestrant 2pyrotinib 1Trastuzumab 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Estrogen Receptor-positive Breast Cancer × palbociclib × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

NCT05076695 2021-10-13

NeoTPPF

Fudan University

Phase 2 Unknown
37 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡